Also known as: N-Acetyl Semax (variant)
A synthetic fragment of ACTH used in Russia for stroke recovery and cognitive support.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Raises BDNF and NGF, supports dopamine and serotonin systems, and protects neurons after oxygen loss.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Focus, memory & brain | B | Human trials (smaller, mixed, or approved outside the US) |
| Stress, anxiety & mood | C | Limited human data, case series or practitioner reports |
| Nerve pain & neuropathy | C | Limited human data, case series or practitioner reports |
At a glance
- Route
- Nasal spray or drops
- Half-life
- Minutes; effects last 20+ hours
Reported dosing
Cognition: 200 to 900 mcg daily intranasally (0.1% solution). Stroke: much higher doses (1% solution) in hospital.
Timing: Morning or early afternoon; can be stimulating.
Cycle: 10 to 14 days on, then a break.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Nasal irritation
- Restlessness or poor sleep if taken late
Who should avoid it
- Seizure disorders
- Acute psychosis
Often combined with
With Selank to balance stimulation.
Key findings
Russian clinical studies report better stroke recovery and attention. Independent Western trials are lacking.
2026 update
Apr 2026: moved off the Category 2 list. Jul 2026: advisory committee recommended compounding; FDA decision pending.
Where it is legal (Oct 2026)
| US | Pending |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Approved in Russia and CIS countries.
Sources
Open Semax in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.